Carsgen's allogeneic cd19/cd20 car-t therapy administers first dose in a patient with autoimmune disease

Shanghai , feb. 27, 2025 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on innovative car t-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that kj-c2219, an allogeneic car-t therapy targeting cd19/cd20, has administered at the starting dose specified in the clinical protocol to the first patient with systemic lupus erythematosus (sle) in an investigator-initiated trial (iit). kj-c2219 is developed using thank-u plus™ platform.
CAR Ratings Summary
CAR Quant Ranking